We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Lantern Pharma, a clinical-stage biopharma company using its RADR artificial intelligence platform to advance cancer drug development, is launching the development of its ADC (Antibody Drug Conjugate) program through an evaluation and potential ...